{"id":65273,"date":"2026-05-14T13:27:28","date_gmt":"2026-05-14T05:27:28","guid":{"rendered":"https:\/\/flcube.com\/?p=65273"},"modified":"2026-05-14T13:27:29","modified_gmt":"2026-05-14T05:27:29","slug":"zhongsheng-pharmas-onradivir-anruiwei-receives-nmpa-review-acceptance-for-pediatric-influenza-a-indication-phase-iii-data-shows-favorable-efficacy-vs-tamiflu","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65273","title":{"rendered":"Zhongsheng Pharma&#8217;s Onradivir (Anruiwei) Receives NMPA Review Acceptance for Pediatric Influenza A Indication \u2013 Phase III Data Shows Favorable Efficacy vs. Tamiflu"},"content":{"rendered":"\n<p><strong>Guangdong Zhongsheng Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/002317:SHE\">SHE: 002317<\/a>) announced that China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has accepted for review a new indication filing for its <strong>Category 1 drug candidate Anruiwei (onradivir)<\/strong>. The sought indication is for the treatment of <strong>uncomplicated acute influenza A in pediatric patients aged 2 to 11 years<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-status-amp-clinical-development\">Regulatory Status &amp; Clinical Development<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Milestone<\/th><th>Status<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>NMPA Filing<\/strong><\/td><td>Accepted for review<\/td><td>Pediatric influenza A indication (ages 2-11)<\/td><\/tr><tr><td><strong>Drug Classification<\/strong><\/td><td>Category 1 innovative drug<\/td><td>Highest priority classification in China<\/td><\/tr><tr><td><strong>Clinical Trial Design<\/strong><\/td><td>Phase III, active comparator<\/td><td>vs. Roche&#8217;s Tamiflu (oseltamivir phosphate powder)<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>120 pediatric participants<\/td><td>Ages 2-11 with uncomplicated acute influenza A<\/td><\/tr><tr><td><strong>Formulation Advantage<\/strong><\/td><td>Oral suspension<\/td><td>Facilitates administration for pediatric patients and those with dysphagia<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-trial-results-amp-competitive-positioning\">Clinical Trial Results &amp; Competitive Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Comparator:<\/strong> <strong>Roche&#8217;s Tamiflu<\/strong> (oseltamivir phosphate powder for oral suspension) \u2013 current standard of care<\/li>\n\n\n\n<li><strong>Primary Endpoint:<\/strong> Met intended objectives with <strong>positive top-line data<\/strong><\/li>\n\n\n\n<li><strong>Efficacy:<\/strong> Demonstrated <strong>favorable efficacy<\/strong> comparable to or exceeding Tamiflu<\/li>\n\n\n\n<li><strong>Safety Profile:<\/strong> Showed <strong>good safety profile<\/strong> suitable for pediatric use<\/li>\n\n\n\n<li><strong>Patient-Centric Design:<\/strong> Oral suspension formulation addresses key administration challenges in young children<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-strategic-implications\">Market Opportunity &amp; Strategic Implications<\/h2>\n\n\n\n<p><strong>Pediatric Influenza Market Context:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Annual influenza seasons create consistent demand for effective pediatric antivirals<\/li>\n\n\n\n<li>Limited treatment options specifically approved for children under 12 years<\/li>\n\n\n\n<li>Parent and physician preference for easy-to-administer formulations drives market adoption<\/li>\n<\/ul>\n\n\n\n<p><strong>Competitive Advantages:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Category 1 designation<\/strong> provides regulatory exclusivity and pricing advantages in China<\/li>\n\n\n\n<li><strong>Oral suspension formulation<\/strong> offers superior patient compliance compared to capsules requiring opening\/mixing<\/li>\n\n\n\n<li><strong>Domestic innovation<\/strong> aligns with China&#8217;s push for homegrown pharmaceutical solutions<\/li>\n\n\n\n<li><strong>Phase III success against Tamiflu<\/strong> validates clinical competitiveness against established global standard<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-commercial-outlook-amp-pipeline-strategy\">Commercial Outlook &amp; Pipeline Strategy<\/h2>\n\n\n\n<p>This pediatric indication represents a strategic expansion of Zhongsheng&#8217;s onradivir franchise beyond adult populations. With influenza remaining a significant public health concern in China, particularly among school-aged children, the potential market opportunity is substantial.<\/p>\n\n\n\n<p>The company&#8217;s ability to demonstrate non-inferiority or superiority to Tamiflu in a head-to-head Phase III trial positions onradivir as a potential first-line alternative for pediatric influenza treatment in the Chinese market.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, clinical development outcomes, and commercial expectations for onradivir. Actual results may differ due to risks including NMPA review decisions, competitive dynamics, and market adoption patterns.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/\u4f17\u751f\u836f\u4e1a\uff1a\u5173\u4e8e\u6602\u62c9\u5730\u97e6\u9897\u7c92\uff08ZSP1273\u9897\u7c92\uff09\u65b0\u836f\u4e0a\u5e02\u7533\u8bf7\u83b7\u5f97\u53d7\u7406\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u4f17\u751f\u836f\u4e1a\uff1a\u5173\u4e8e\u6602\u62c9\u5730\u97e6\u9897\u7c92\uff08ZSP1273\u9897\u7c92\uff09\u65b0\u836f\u4e0a\u5e02\u7533\u8bf7\u83b7\u5f97\u53d7\u7406\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-fbf96ff8-3877-4ccf-a0c3-4250a9df3d30\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/\u4f17\u751f\u836f\u4e1a\uff1a\u5173\u4e8e\u6602\u62c9\u5730\u97e6\u9897\u7c92\uff08ZSP1273\u9897\u7c92\uff09\u65b0\u836f\u4e0a\u5e02\u7533\u8bf7\u83b7\u5f97\u53d7\u7406\u7684\u516c\u544a.pdf\">\u4f17\u751f\u836f\u4e1a\uff1a\u5173\u4e8e\u6602\u62c9\u5730\u97e6\u9897\u7c92\uff08ZSP1273\u9897\u7c92\uff09\u65b0\u836f\u4e0a\u5e02\u7533\u8bf7\u83b7\u5f97\u53d7\u7406\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/\u4f17\u751f\u836f\u4e1a\uff1a\u5173\u4e8e\u6602\u62c9\u5730\u97e6\u9897\u7c92\uff08ZSP1273\u9897\u7c92\uff09\u65b0\u836f\u4e0a\u5e02\u7533\u8bf7\u83b7\u5f97\u53d7\u7406\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-fbf96ff8-3877-4ccf-a0c3-4250a9df3d30\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) announced that China&#8217;s National Medical Products Administration (NMPA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[38,68,1197,399],"class_list":["post-65273","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-market-approval-filings","tag-pediatric-drugs","tag-she-002317","tag-zhongsheng-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Zhongsheng Pharma&#039;s Onradivir (Anruiwei) Receives NMPA Review Acceptance for Pediatric Influenza A Indication \u2013 Phase III Data Shows Favorable Efficacy vs. Tamiflu - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) announced that China&#039;s National Medical Products Administration (NMPA) has accepted for review a new indication filing for its Category 1 drug candidate Anruiwei (onradivir). The sought indication is for the treatment of uncomplicated acute influenza A in pediatric patients aged 2 to 11 years.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65273\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zhongsheng Pharma&#039;s Onradivir (Anruiwei) Receives NMPA Review Acceptance for Pediatric Influenza A Indication \u2013 Phase III Data Shows Favorable Efficacy vs. Tamiflu\" \/>\n<meta property=\"og:description\" content=\"Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) announced that China&#039;s National Medical Products Administration (NMPA) has accepted for review a new indication filing for its Category 1 drug candidate Anruiwei (onradivir). The sought indication is for the treatment of uncomplicated acute influenza A in pediatric patients aged 2 to 11 years.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65273\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-14T05:27:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-14T05:27:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65273#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65273\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Zhongsheng Pharma&#8217;s Onradivir (Anruiwei) Receives NMPA Review Acceptance for Pediatric Influenza A Indication \u2013 Phase III Data Shows Favorable Efficacy vs. Tamiflu\",\"datePublished\":\"2026-05-14T05:27:28+00:00\",\"dateModified\":\"2026-05-14T05:27:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65273\"},\"wordCount\":397,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Market approval filings\",\"Pediatric drugs\",\"SHE: 002317\",\"Zhongsheng Pharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65273#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65273\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65273\",\"name\":\"Zhongsheng Pharma's Onradivir (Anruiwei) Receives NMPA Review Acceptance for Pediatric Influenza A Indication \u2013 Phase III Data Shows Favorable Efficacy vs. Tamiflu - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-14T05:27:28+00:00\",\"dateModified\":\"2026-05-14T05:27:29+00:00\",\"description\":\"Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) announced that China's National Medical Products Administration (NMPA) has accepted for review a new indication filing for its Category 1 drug candidate Anruiwei (onradivir). The sought indication is for the treatment of uncomplicated acute influenza A in pediatric patients aged 2 to 11 years.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65273#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65273\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65273#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zhongsheng Pharma&#8217;s Onradivir (Anruiwei) Receives NMPA Review Acceptance for Pediatric Influenza A Indication \u2013 Phase III Data Shows Favorable Efficacy vs. Tamiflu\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Zhongsheng Pharma's Onradivir (Anruiwei) Receives NMPA Review Acceptance for Pediatric Influenza A Indication \u2013 Phase III Data Shows Favorable Efficacy vs. Tamiflu - Insight, China&#039;s Pharmaceutical Industry","description":"Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) announced that China's National Medical Products Administration (NMPA) has accepted for review a new indication filing for its Category 1 drug candidate Anruiwei (onradivir). The sought indication is for the treatment of uncomplicated acute influenza A in pediatric patients aged 2 to 11 years.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65273","og_locale":"en_US","og_type":"article","og_title":"Zhongsheng Pharma's Onradivir (Anruiwei) Receives NMPA Review Acceptance for Pediatric Influenza A Indication \u2013 Phase III Data Shows Favorable Efficacy vs. Tamiflu","og_description":"Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) announced that China's National Medical Products Administration (NMPA) has accepted for review a new indication filing for its Category 1 drug candidate Anruiwei (onradivir). The sought indication is for the treatment of uncomplicated acute influenza A in pediatric patients aged 2 to 11 years.","og_url":"https:\/\/flcube.com\/?p=65273","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-14T05:27:28+00:00","article_modified_time":"2026-05-14T05:27:29+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65273#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65273"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Zhongsheng Pharma&#8217;s Onradivir (Anruiwei) Receives NMPA Review Acceptance for Pediatric Influenza A Indication \u2013 Phase III Data Shows Favorable Efficacy vs. Tamiflu","datePublished":"2026-05-14T05:27:28+00:00","dateModified":"2026-05-14T05:27:29+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65273"},"wordCount":397,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Market approval filings","Pediatric drugs","SHE: 002317","Zhongsheng Pharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65273#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65273","url":"https:\/\/flcube.com\/?p=65273","name":"Zhongsheng Pharma's Onradivir (Anruiwei) Receives NMPA Review Acceptance for Pediatric Influenza A Indication \u2013 Phase III Data Shows Favorable Efficacy vs. Tamiflu - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-14T05:27:28+00:00","dateModified":"2026-05-14T05:27:29+00:00","description":"Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) announced that China's National Medical Products Administration (NMPA) has accepted for review a new indication filing for its Category 1 drug candidate Anruiwei (onradivir). The sought indication is for the treatment of uncomplicated acute influenza A in pediatric patients aged 2 to 11 years.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65273#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65273"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65273#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Zhongsheng Pharma&#8217;s Onradivir (Anruiwei) Receives NMPA Review Acceptance for Pediatric Influenza A Indication \u2013 Phase III Data Shows Favorable Efficacy vs. Tamiflu"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65273","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65273"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65273\/revisions"}],"predecessor-version":[{"id":65276,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65273\/revisions\/65276"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65273"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65273"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65273"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}